CYDY News and Press, CytoDyn Inc From 02/20/19

VANCOUVER, Washington, Feb. 20, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that it was able to reduce by more than 98% the incidence of human breast cance...

VANCOUVER, Washington, Feb. 19, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) announces that Nader Pourhassan, Ph.D., director, President and CEO, and Richard Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., Chief Medical Officer and Vice Chairman of the Board, will host an inve...

Gilead Sciences (GILD) has a very tough road ahead after its latest earnings report. The earnings for the fourth quarter were mixed, but the company needs to take drastic action to redeem itself. The revenue may have come in over expectations, but it won't be long until Gilead finds itself i...

CytoDyn ( OTCQB:CYDY ) will conduct 8 pre-clinical studies on melanoma cancer, pancreatic, breast, prostate, colon, lung, liver and stomach cancer. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

VANCOUVER, Washington, Feb. 19, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody, leronlimab (PRO 140), for multiple therapeutic indications, announced that its new laboratory located in Philadelphia under th...

My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercept’s Ocaliva, a “NASH cirrhosis” drug candidate, is haile...

PHOENIX, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed CytoDyn Inc. (CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab (PRO 140), a novel humanized monoclonal antibody targeting the CCR5 co...

VANCOUVER, Washington, Feb. 08, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), CytoDyn, a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that it will be presenting a company overview at BIO CEO & Investo...

Successful interim results in the 700 mg monotherapy arm prompted the FDA to allow CytoDyn to switch all remaining combination therapy patients from CD02-Extension study from 350 mg to 700 mg dose CytoDyn is in negotiations for post-approval sales distribution channels with potential u...

VANCOUVER, Washington, Jan. 25, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that it will be presenting an update on the company’s clinical dev...